Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence

Seong Hee Kang; Hyeki Cho; Eun Ju Cho; Joon Yeul Nam; Young Chang; Young Youn Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon

doi:10.18632/oncotarget.23384

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/17/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Clinical Research Papers:

Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence

Seong Hee Kang, Hyeki Cho, Eun Ju Cho _, Joon Yeul Nam, Young Chang, Young Youn Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh and Jung-Hwan Yoon

Seong Hee Kang1,3,*, Hyeki Cho1,*, Eun Ju Cho1, Joon Yeul Nam1, Young Chang1, Young Youn Cho1, Jeong-Hoon Lee1, Su Jong Yu1, Yoon Jun Kim1, Nam-Joon Yi2, Kwang-Woong Lee2, Kyung-Suk Suh2 and Jung-Hwan Yoon1

1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

2Department of Surgery, Seoul National University College of Medicine, Seoul, Korea

3Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

*These authors contributed equally to this work

Correspondence to:

Eun Ju Cho, email: [email protected]

Keywords: sorafenib; efficacy; liver transplantation; hepatocellular carcinoma; recurrence

Received: September 01, 2017 Accepted: December 04, 2017 Epub: December 17, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23384

Publication Alerts

Post-Publication Promotion

Withdrawal Notice

Clinical Research Papers:

Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence